TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the first three evaluable patients treated in the frontline setting. Speaking duri

TuHURA reveals initial data from study of adjunct therapy to Keytruda in MCC - BioTuesdays

TuHURA Biosciences (NASDAQ: HURA) announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment of metastatic Merkel Cell Carcinoma (MCC). According to TuHURA, results showed that each patient achieved a major objective anti-tumor response, with all three responses meeting the criteria for […]